Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 1 , Pages 24-32 , January 2010

Effects of Lisdexamfetamine Dimesylate Treatment for ADHD on Growth

  • Stephen V. Faraone, Ph.D.

      Affiliations

    • State University of New York Upstate Medical University
    • Corresponding Author InformationCorrespondence to Dr. Stephen V. Faraone, State University of New York Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210
    • ,
  • Thomas J. Spencer, M.D.

      Affiliations

    • Massachusetts General Hospital and Harvard Medical School
    • ,
  • Scott H. Kollins, Ph.D.

      Affiliations

    • Duke University Medical School Center
    • ,
  • Stephen J. Glatt, Ph.D.

      Affiliations

    • State University of New York Upstate Medical University

,Accepted 13 October 2009.

References 

  1. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47(9):994–1009
  2. MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113(4):762–769
  3. Swanson JM, Elliott GR, Greenhill LL, et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry. 2007;46(8):1015–1027
  4. Faraone SV, Biederman J, Monuteaux M, Spencer T. Long-term effects of extended-release mixed amphetamine salts treatment of attention-deficit/hyperactivity disorder on growth. J Child Adolesc Psychopharmacol. 2005;15(2):191–202
  5. Spencer T, Faraone SV, Biederman J, et al. Does prolonged stimulant therapy suppress growth in children with ADHD? (Analysis of data from 21 months of therapy with once-daily OROS® MPH). J Am Acad Child Adolesc Psychiatry. 2006;45(5):527–537
  6. Faraone SV, Giefer EE. Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1138–1147
  7. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364–1373
  8. Faraone SV. Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder. Expert Opin Pharmacother. 2008;9(9):1565–1574
  9. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y. Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry. 2007;62(9):970–976
  10. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and safety of lisdexamfetamine (LDX; NRP104) in children with attention-deficit/hyperactivity disorder: a phase 3, randomized, multicenter, double-blind, parallel-group study. Clin Ther. 2007;29(3):450–463
  11. Kuczmarski RJ, Ogden CL, Guo L, et al. CDC growth charts for the United States: methods and development (National Center for Health Statistics). Vital Health Stat. 2000;11(246):1–201
  12. Swanson J, Greenhill L, Wigal T, et al. Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1304–1313
  13. Schertz M, Adesman AR, Alfieri NE, Bienkowski RS. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics. 1996;98(4, pt 1):763–769
  14. Satterfield JH, Cantwell DP, Schell A, Blaschke T. Growth of hyperactive children treated with methylphenidate. Arch Gen Psychiatry. 1979;36:212–217
  15. Sund AM, Zeiner P. Does extended medication with amphetamine or methylphenidate reduce growth in hyperactive children?. Nord J Psychiatry. 2002;56(1):53–57
  16. Faraone SV, Giefer EE. Long term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1138–1147
  17. Swanson JM, Ruff DD, Feldman PD, Furr AJ, Allen AJ. Characterization of growth in children with ADHD. Paper presented at the American Academy of Child and Adolescent Psychiatry Annual Meeting; Toronto, Canada; 2005.

 This article was reviewed under and accepted by Ad Hoc Editor Kenneth Towbin, M.D.

 This work was supported by Shire Development, Inc.

 This article includes information from NRP104.302 Interim Analysis of a Long-Term, Open-Label, Single-Arm Study of Lisdexamfetamine (LDX), an Amphetamine Prodrug, in Children With ADHD: This study was started on November 21, 2004, and completed on March 23, 2006, and at the time of the study, industry standards and Shire standard operating procedures did not require posting of open-label studies.

 Disclosure: In the past year, Dr. Faraone has served as a consultant and on advisory boards for Eli Lilly & Company, Ortho-McNeil, and Shire, and has received research support from Eli Lilly & Company, Pfizer, Shire, and the National Institutes of Health. In previous years, Dr. Faraone has served as a consultant, on advisory boards, or on the speakers' bureau for Shire, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly & Company. In previous years, he has received research support from Eli Lilly, Shire, Pfizer, and the National Institutes of Health. Dr. Glatt has received research support from the National Institutes of Health. He has received research support from, served as a consultant for, or served on the speakers' bureau for Shire Laboratories, and the National Institutes of Health. Dr. Spencer receives research support from Shire Laboratories, Cephalon, Eli Lilly & Company, GlaxoSmithKline, Janssen, McNeil Pharmaceutical, Novartis Pharmaceuticals, Pfizer, and the National Institute of Mental Health. He has served on the speakers' bureaus for Shire Laboratories, Eli Lilly & Company, GlaxoSmithKline, Janssen, McNeil Pharmaceutical, and Novartis Pharmaceuticals. He has served on the advisory boards for Shire Laboratories, Cephalon, Eli Lilly & Company, GlaxoSmithKline, Janssen, McNeil Pharmaceutical, Novartis Pharmaceuticals, and Pfizer. Dr. Kollins has received research support from Addrenex Pharmaceuticals, Comentis, Shire Pharmaceuticals, the National Institute on Drug Abuse, the National Institute of Mental Health, the National Institute of Neurological Disorders and Stroke, the National Institute of Environmental Health Services, and the Environmental Protection Agency. Dr. Kollins has served as a consultant for Addrenex Pharmaceuticals, Comentis, Shire Pharmaceuticals, and the National Institute on Drug Abuse.

PII: S0890-8567(09)00009-4

doi: 10.1016/j.jaac.2009.10.003

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 1 , Pages 24-32 , January 2010

Article Tools

* Image Usage & Resolution